Diabetestherapie bei herzkranken Patienten

Wenn es nicht möglich ist, die glykämischen Behandlungsziele mit nicht-medikamentösen Maßnahmen zu erreichen, soll innerhalb weniger Monate – oder bei Stoffwechseldekompensation sofort – mit einer medikamentösen Diabetestherapie begonnen werden. Dabei müssen individualisierte Therapieziele unter Einbezug des individuellen kardiovaskulären und renalen Risikos definiert werden.

Abstract

If it is not possible to achieve the glycaemic treatment goals with non-medicinal measures, pharmacological therapy should be started within a few months – or immediately in case of metabolic decompensation. Individualized therapy goals must be defined taking into account the individual cardiovascular and renal risk.

Schlüsselwörter

Diabetes mellitus - orale Diabetestherapie - Hypoglykämierisiko - kardiovaskuläre Erkrankung - Niereninsuffizienz

Keywords

diabetes mellitus - oral diabetes therapy - hypoglycemic risk - cardiovascular disease - renal insufficiency

• Literatur

• 1 Draznin B, Aroda VR. American Diabetes Association Professional Practice Committee. et al. 9. pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care 2022; 45 (Suppl. 01) S125-S143
• 2 Buse JB, Wexler DJ, Tsapas A. et al. Correction to: 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia 2020; 63 (08) 1667
• 3 Landgraf R, Aberle J, Birkenfeld AL. et al. Therapie des Typ-2-Diabetes. Diabetologie 2022; 17 (Suppl. 02) S159-S204
• 4 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes – Teilpublikation der Langfassung. 2. Auflage. Version 1.. Accessed December 19, 2022 at: www.leitlinien.de/diabetes 2021
• 5 Cosentino F, Grant PJ, Aboyans V. et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41 (02) 255-323
• 6 UKPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865
• 7 Breuer TG, Meier JJ. Inpatient treatment of type 2 diabetes. Dtsch Arztebl Int 2012; 109: 466-474
• 8 Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia 2017; 60 (09) 1586-1593
• 9 Rote-Liste-Service-GmbH. Fachinformationsverzeichnis Deutschland. . Accessed October 27, 2022 at: http://www.fachinfo.de
• 10 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale Versorgungsleitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter – Kurzfassung Version 1.4.2012 . Accessed October 27, 2022 at: http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_nephro/ index_html
• 11 Eurich DT, Majumdar SR, McAlister FA. et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-2351
• 12 McGill JB. Pharmacotherapy in type 2 diabetes: a functional schema for drug classification. Curr Diabetes Rev 2012; 8: 257-267
• 13 Bannister CA, Holden SE, Jenkins-Jones S. et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 2014; 16 (11) 1165-1173
• 14 Schernthaner G. Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 2010; 160: 8-19
• 15 Meier JJ, Gallwitz B, Schmidt WE. et al. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. Heart 2004; 90: 9-12
• 16 Bennett WL, Maruthur NM, Singh S. et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602-613
• 17 Gallwitz B. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetesmellitus therapy. Expert Opin Investig Drugs 2011; 20: 723-732
• 18 Gallwitz B. Clinical Use of DPP-4 Inhibitors. Front Endocrinol (Lausanne) 2019; 10: 389
• 19 Rosenstock J, Kahn SE, Johansen OE. et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 2019; 322 (12) 1155-1166
• 20 Nauck MA, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab 2021; 46: 101102
• 21 Lee MMY, Kristensen SL, Gerstein HC. et al. Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes Metab Syndr 2022; 16 (01) 102382
• 22 Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 2014; 8: 1335-1380
• 23 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373 (22) 2117-2128
• 24 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380 (04) 347-357
• 25 Cannon CP, Pratley R, Dagogo-Jack S. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383 (15) 1425-1435
• 26 Palmer SC, Tendal B, Mustafa RA. et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021; 372: m4573